2cureX Investor Relations Material
Latest events
Investor Update
2cureX
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from 2cureX
Access all reports
2cureX AB is a medtech company focused on improving cancer treatment through functional drug sensitivity testing. Its flagship product, IndiTreat, is an in vitro diagnostic (IVD) test that helps predict a cancer patient’s response to different drugs, enabling personalized treatment plans. IndiTreat is designed to assist in treating colorectal, ovarian, and pancreatic cancers, among others. The company is headuqartered in Copenhagen, Denmark, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
2CUREX
Country
🇸🇪 Sweden